secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001437749-23-007580
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin reports FY 2022 net loss of $29.0M; cash $43.1M, runway into Q3 2024
------------------------------------------------------------------------------

- Net loss $29.0M for 2022 vs $6.7M in 2021; R&D expense $19.0M (up $4.6M), G&A $11.5M.
- Cash and equivalents $43.1M as of Dec 31, 2022; sufficient to fund ops into Q3 2024.
- Annamycin Phase 1/2 trial in AML approved in Italy; first subjects dosed.
- FDA granted Fast Track Designation for WP1122 in Glioblastoma Multiforme.
- European Phase 1 Annamycin trial reported 80% overall response rate in final cohort.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923007580/0001437749-23-007580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923007580/mbrx20230321_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-007580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer